norisoboldine and Colitis--Ulcerative

norisoboldine has been researched along with Colitis--Ulcerative* in 3 studies

Other Studies

3 other study(ies) available for norisoboldine and Colitis--Ulcerative

ArticleYear
Discovery of Norisoboldine Analogue III
    Journal of medicinal chemistry, 2023, 05-25, Volume: 66, Issue:10

    Topics: Alkaloids; Animals; Aryl Hydrocarbon Receptor Nuclear Translocator; Cell Differentiation; Colitis, Ulcerative; Mice; Receptors, Aryl Hydrocarbon

2023
Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.
    Bioorganic & medicinal chemistry letters, 2021, 04-01, Volume: 37

    In this study, we used chemical modification to improve the pharmacological activity of norisoboldine (NOR). A new NOR-benzoic acid derivative, named DC-01, showed more potent induction of Treg cell differentiation than NOR. The in vitro effective concentration of DC-01 (1 μM) is about an order of magnitude lower than that of NOR (10 μM). DC-01 (28, 56 mg/kg) showed better amelioration of dextran sodium sulfate-induced colitis in mice than NOR (20, 40 mg/kg), and DC-01 (28 mg/kg) increased the number of Treg cells slightly better than NOR (20 mg/kg). In summary, DC-01 exerts more potent induction of Treg cell generation, which might be a candidate drug for the treatment of inflammation- and immune-related diseases.

    Topics: Alkaloids; Animals; Cell Differentiation; Cell Survival; Colitis, Ulcerative; Dextran Sulfate; Dose-Response Relationship, Drug; Mice; Molecular Structure; Structure-Activity Relationship; T-Lymphocytes, Regulatory; Tumor Cells, Cultured

2021
Norisoboldine ameliorates DSS-induced ulcerative colitis in mice through induction of regulatory T cells in colons.
    International immunopharmacology, 2015, Volume: 29, Issue:2

    Norisoboldine (NOR), the main active constituent of Radix Linderae, was previously demonstrated to ameliorate collagen-induced arthritis in rats through regulating the imbalance of T cells in intestines, which implied its therapeutic potential in inflammatory bowel disease. Here, we investigated the effect of NOR on ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) in mice. Results showed that NOR (20, 40mg/kg) markedly reduced the symptoms of colitis, the levels of IL-1β and TNF-α, and the activation of ERK, p38 MAPK and NF-κB-p65. NOR only slightly decreased the levels of IFN-γ and IL-17A in mouse colons, but it dramatically increased the level of IL-10 at both protein and mRNA grades. Consistently, NOR increased the number of CD4(+)CD25(+)Foxp3(+) Treg cells more obviously than it decreased that of CD4(+)IL-17(+) Th17 cells in mesenteric lymph nodes (MLNs) and colonic lamina proprias (LPs) of colitis mice, and promoted the expression of Foxp3 mRNA in colon tissues. It could facilitate the in vitro differentiation of Treg cells from naive T cells and promote the phosphorylations of Smad2/3 in colon tissues of colitis mice. On the other hand, NOR did not affect the expressions of homing receptors CCR9 and α4β7 in SPs, and homing ligands CCL25 and Madcam-1 in MLNs and colonic LPs, suggesting that the increase of Treg cells in colons by NOR was not due to gut homing. In conclusion, NOR can ameliorate DSS-induced UC in mice, and the mechanisms involve reduction of pro-inflammatory cytokines and selective induction of Treg cells in colons.

    Topics: Alkaloids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Lymph Nodes; Male; Mice; Mice, Inbred C57BL; Signal Transduction; T-Lymphocytes, Regulatory

2015